ANI Pharmaceuticals (ANIP) Competitors

$82.72 -0.22 (-0.27%)

Closing price 06/24/2026 04:00 PM Eastern

Extended Trading

$84.14 +1.42 (+1.71%)

As of 06/24/2026 07:26 PM Eastern

ANIP vs. ADMA, ANVS, KYMR, PTGX, and SYRE

Should you buy ANI Pharmaceuticals stock or one of its competitors? MarketBeat compares ANI Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ANI Pharmaceuticals include ADMA Biologics (ADMA), Annovis Bio (ANVS), Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.

How does ANI Pharmaceuticals compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and ANI Pharmaceuticals (NASDAQ:ANIP) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

ADMA Biologics presently has a consensus target price of $19.67, indicating a potential upside of 126.05%. ANI Pharmaceuticals has a consensus target price of $107.33, indicating a potential upside of 29.75%. Given ADMA Biologics' higher possible upside, analysts plainly believe ADMA Biologics is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
ANI Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

ADMA Biologics has a net margin of 32.43% compared to ANI Pharmaceuticals' net margin of 9.98%. ADMA Biologics' return on equity of 39.98% beat ANI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.43%	39.98%	28.08%
ANI Pharmaceuticals	9.98%	27.51%	10.02%

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ADMA Biologics has higher earnings, but lower revenue than ANI Pharmaceuticals. ADMA Biologics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	3.95	$146.93M	$0.68	12.79
ANI Pharmaceuticals	$883.37M	2.13	$78.34M	$3.95	20.94

In the previous week, ADMA Biologics had 37 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 37 mentions for ADMA Biologics and 0 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 1.75 beat ADMA Biologics' score of 0.06 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
ADMA Biologics	Neutral
ANI Pharmaceuticals	Very Positive

ADMA Biologics has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market.

Summary

ADMA Biologics and ANI Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

In the previous week, ANI Pharmaceuticals' average media sentiment score of 1.75 beat Annovis Bio's score of 0.00 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Annovis Bio	Neutral
ANI Pharmaceuticals	Very Positive

ANI Pharmaceuticals has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A
ANI Pharmaceuticals	$883.37M	2.13	$78.34M	$3.95	20.94

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

ANI Pharmaceuticals has a net margin of 9.98% compared to Annovis Bio's net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.51% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-318.08%	-215.47%
ANI Pharmaceuticals	9.98%	27.51%	10.02%

Annovis Bio has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market.

Annovis Bio currently has a consensus target price of $13.50, indicating a potential upside of 696.46%. ANI Pharmaceuticals has a consensus target price of $107.33, indicating a potential upside of 29.75%. Given Annovis Bio's higher probable upside, equities analysts clearly believe Annovis Bio is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
ANI Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

ANI Pharmaceuticals beats Annovis Bio on 11 of the 14 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Kymera Therapeutics?

ANI Pharmaceuticals (NASDAQ:ANIP) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

ANI Pharmaceuticals has a net margin of 9.98% compared to Kymera Therapeutics' net margin of -611.94%. ANI Pharmaceuticals' return on equity of 27.51% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	9.98%	27.51%	10.02%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

ANI Pharmaceuticals has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.02, meaning that its stock price is 102% more volatile than the broader market.

In the previous week, Kymera Therapeutics had 17 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 17 mentions for Kymera Therapeutics and 0 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 1.75 beat Kymera Therapeutics' score of 0.08 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
ANI Pharmaceuticals	Very Positive
Kymera Therapeutics	Neutral

76.1% of ANI Pharmaceuticals shares are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ANI Pharmaceuticals has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	2.13	$78.34M	$3.95	20.94
Kymera Therapeutics	$39.21M	209.52	-$311.35M	-$3.57	N/A

ANI Pharmaceuticals presently has a consensus price target of $107.33, suggesting a potential upside of 29.75%. Kymera Therapeutics has a consensus price target of $117.14, suggesting a potential upside of 17.29%. Given ANI Pharmaceuticals' higher possible upside, equities analysts clearly believe ANI Pharmaceuticals is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96

Summary

ANI Pharmaceuticals beats Kymera Therapeutics on 10 of the 17 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Protagonist Therapeutics?

ANI Pharmaceuticals (NASDAQ:ANIP) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

ANI Pharmaceuticals has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.85, suggesting that its stock price is 85% more volatile than the broader market.

ANI Pharmaceuticals currently has a consensus price target of $107.33, suggesting a potential upside of 29.75%. Protagonist Therapeutics has a consensus price target of $115.21, suggesting a potential downside of 5.68%. Given ANI Pharmaceuticals' higher probable upside, analysts clearly believe ANI Pharmaceuticals is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

ANI Pharmaceuticals has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	2.13	$78.34M	$3.95	20.94
Protagonist Therapeutics	$46.02M	170.70	-$130.15M	-$1.81	N/A

ANI Pharmaceuticals has a net margin of 9.98% compared to Protagonist Therapeutics' net margin of -154.88%. ANI Pharmaceuticals' return on equity of 27.51% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	9.98%	27.51%	10.02%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Protagonist Therapeutics had 6 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 6 mentions for Protagonist Therapeutics and 0 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 1.75 beat Protagonist Therapeutics' score of 1.26 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
ANI Pharmaceuticals	Very Positive
Protagonist Therapeutics	Positive

Summary

ANI Pharmaceuticals beats Protagonist Therapeutics on 10 of the 17 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and ANI Pharmaceuticals (NASDAQ:ANIP) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

Spyre Therapeutics has a beta of 3.05, indicating that its stock price is 205% more volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market.

In the previous week, Spyre Therapeutics had 10 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 10 mentions for Spyre Therapeutics and 0 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 1.75 beat Spyre Therapeutics' score of 0.53 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Spyre Therapeutics	Positive
ANI Pharmaceuticals	Very Positive

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Spyre Therapeutics currently has a consensus target price of $95.83, suggesting a potential upside of 11.12%. ANI Pharmaceuticals has a consensus target price of $107.33, suggesting a potential upside of 29.75%. Given ANI Pharmaceuticals' higher possible upside, analysts clearly believe ANI Pharmaceuticals is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
ANI Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

ANI Pharmaceuticals has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	8,414.70	-$155.20M	-$2.08	N/A
ANI Pharmaceuticals	$883.37M	2.13	$78.34M	$3.95	20.94

ANI Pharmaceuticals has a net margin of 9.98% compared to Spyre Therapeutics' net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.51% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
ANI Pharmaceuticals	9.98%	27.51%	10.02%

Summary

ANI Pharmaceuticals beats Spyre Therapeutics on 9 of the 17 factors compared between the two stocks.

Get ANI Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANIP vs. The Competition

Export

Metric	ANI Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.89B	$3.49B	$6.74B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	20.94	20.50	25.14	23.95
Price / Sales	2.13	328.65	531.12	107.90
Price / Cash	8.35	130.96	45.29	53.76
Price / Book	3.44	8.26	10.77	6.41
Net Income	$78.34M	$23.91M	$3.56B	$337.14M
7 Day Performance	4.06%	2.12%	1.00%	-1.06%
1 Month Performance	N/A	2.40%	0.81%	0.49%
1 Year Performance	25.50%	57.09%	30.27%	28.43%

ANI Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANIP ANI Pharmaceuticals	4.4503 of 5 stars	$82.72 -0.3%	$107.33 +29.8%	+23.5%	$1.89B	$883.37M	20.94	600	Positive News Analyst Upgrade
ADMA ADMA Biologics	4.4968 of 5 stars	$8.50 +3.5%	$19.67 +131.4%	-51.3%	$1.90B	$510.17M	12.50	530	Trending News
ANVS Annovis Bio	2.4288 of 5 stars	$1.79 +0.3%	$13.50 +656.3%	-44.2%	$61.67M	N/A	N/A	3
KYMR Kymera Therapeutics	2.0006 of 5 stars	$85.59 -0.7%	$117.14 +36.9%	+111.9%	$7.09B	$39.21M	N/A	170	Insider Trade
PTGX Protagonist Therapeutics	1.4024 of 5 stars	$112.46 +2.4%	$115.21 +2.4%	+127.6%	$7.06B	$46.02M	N/A	120	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANIP) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ANI Pharmaceuticals (ANIP) Competitors

ANIP vs. ADMA, ANVS, KYMR, PTGX, and SYRE

How does ANI Pharmaceuticals compare to ADMA Biologics?

Summary

How does ANI Pharmaceuticals compare to Annovis Bio?

Summary

How does ANI Pharmaceuticals compare to Kymera Therapeutics?

Summary

How does ANI Pharmaceuticals compare to Protagonist Therapeutics?

Summary

How does ANI Pharmaceuticals compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP vs. The Competition

ANI Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ANI Pharmaceuticals (ANIP) Competitors

ANIP vs. ADMA, ANVS, KYMR, PTGX, and SYRE

How does ANI Pharmaceuticals compare to ADMA Biologics?

Do analysts recommend ADMA or ANIP?

Is ADMA or ANIP more profitable?

Do institutionals and insiders have more ownership in ADMA or ANIP?

Which has stronger earnings and valuation, ADMA or ANIP?

Does the media favor ADMA or ANIP?

Which has more risk and volatility, ADMA or ANIP?

Summary

How does ANI Pharmaceuticals compare to Annovis Bio?

Does the media favor ANVS or ANIP?

Which has better earnings and valuation, ANVS or ANIP?

Do institutionals and insiders believe in ANVS or ANIP?

Is ANVS or ANIP more profitable?

Which has more volatility and risk, ANVS or ANIP?

Do analysts rate ANVS or ANIP?

Summary

How does ANI Pharmaceuticals compare to Kymera Therapeutics?

Is ANIP or KYMR more profitable?

Which has more risk and volatility, ANIP or KYMR?

Does the media prefer ANIP or KYMR?

Do insiders & institutionals believe in ANIP or KYMR?

Which has higher earnings & valuation, ANIP or KYMR?

Do analysts recommend ANIP or KYMR?

Summary

How does ANI Pharmaceuticals compare to Protagonist Therapeutics?

Which has more volatility & risk, ANIP or PTGX?

Do analysts recommend ANIP or PTGX?

Which has higher valuation & earnings, ANIP or PTGX?

Is ANIP or PTGX more profitable?

Do insiders & institutionals hold more shares of ANIP or PTGX?

Does the media refer more to ANIP or PTGX?

Summary

How does ANI Pharmaceuticals compare to Spyre Therapeutics?

Which has more volatility and risk, SYRE or ANIP?

Does the media favor SYRE or ANIP?

Do insiders and institutionals have more ownership in SYRE or ANIP?

Do analysts recommend SYRE or ANIP?

Which has better earnings and valuation, SYRE or ANIP?

Is SYRE or ANIP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP vs. The Competition

ANI Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools